Genetically predicted expression levels of ACADM were associated with a decreased IBD risk in sigmoid colon (OR 0.78, 95% CI 0.67–0.91; P = 0.002) and transverse colon tissue (OR 0.72, 95% CI 0.60–0.87; P = 5.15 × 10−4) (Table S19). The gene discussed is ACADM; the disease is inflammatory bowel disease.